Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares IssuedShares OutstandingShares Outstanding
Ratios

Enanta Pharmaceuticals (ENTA) EBIAT (2016 - 2025)

Enanta Pharmaceuticals filings provide 14 years of EBIAT readings, the most recent being -$11.9 million for Q4 2025.

  • On a quarterly basis, EBIAT rose 46.44% to -$11.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$71.5 million, a 31.82% increase, with the full-year FY2025 number at -$81.9 million, up 29.43% from a year prior.
  • EBIAT hit -$11.9 million in Q4 2025 for Enanta Pharmaceuticals, up from -$18.7 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of -$11.9 million in Q4 2025 to a low of -$39.1 million in Q2 2023.
  • Median EBIAT over the past 5 years was -$27.2 million (2022), compared with a mean of -$26.8 million.
  • Biggest five-year swings in EBIAT: tumbled 267.11% in 2021 and later surged 46.44% in 2025.
  • Enanta Pharmaceuticals' EBIAT stood at -$30.1 million in 2021, then increased by 3.75% to -$29.0 million in 2022, then dropped by 15.25% to -$33.4 million in 2023, then skyrocketed by 33.28% to -$22.3 million in 2024, then skyrocketed by 46.44% to -$11.9 million in 2025.
  • The last three reported values for EBIAT were -$11.9 million (Q4 2025), -$18.7 million (Q3 2025), and -$18.3 million (Q2 2025) per Business Quant data.